|
1
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weeks A, Okolowsky N, Golbourn B, Ivanchuk
S, Smith C and Rutka JT: ECT2 and RASAL2 mediate
mesenchymal-amoeboid transition in human astrocytoma cells. Am J
Pathol. 181:662–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Feng M, Bao Y, Li Z, Li J, Gong M, Lam S,
Wang J, Marzese DM, Donovan N, Tan EY, et al: RASAL2 activates RAC1
to promote triple-negative breast cancer progression. J Clin
Invest. 124:5291–5304. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stefanska B, Cheishvili D, Suderman M,
Arakelian A, Huang J, Hallett M, Han ZG, Al-Mahtab M, Akbar SM,
Khan WA, et al: Genome-wide study of hypomethylated and induced
genes in patients with liver cancer unravels novel anticancer
targets. Clin Cancer Res. 20:3118–3132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R,
Zhang W, Lv Z, Zheng S and Zhou L: NDRG1 as a biomarker for
metastasis, recurrence and of poor prognosis in hepatocellular
carcinoma. Cancer Lett. 310:35–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noske A, Denkert C, Schober H, Sers C,
Zhumabayeva B, Weichert W, Dietel M and Wiechen K: Loss of Gelsolin
expression in human ovarian carcinomas. Eur J Cancer. 41:461–469.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bleeker FE, Felicioni L, Buttitta F, Lamba
S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M,
Barbareschi M, et al: AKT1 (E17K) in human solid tumours. Oncogene.
27:5648–5650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sahin F, Kannangai R, Adegbola O, Wang J,
Su G and Torbenson M: mTOR and P70 S6 kinase expression in primary
liver neoplasms. Clin Cancer Res. 10:8421–8425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Z, Zhang Y, Sun XX, Ma X and Chen
ZN: microRNA-146a inhibits cancer metastasis by downregulating VEGF
through dual pathways in hepatocellular carcinoma. Mol Cancer.
14:52015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yunqiao L, Vanke H, Jun X and Tangmeng G:
MicroRNA-206, down-regulated in hepatocellular carcinoma,
suppresses cell proliferation and promotes apoptosis.
Hepatogastroenterology. 61:1302–1307. 2014.
|
|
15
|
Wei W, Wanjun L, Hui S, Dongyue C, Xinjun
Y and Jisheng Z: miR-203 inhibits proliferation of HCC cells by
targeting survivin. Cell Biochem Funct. 31:82–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wan D, Shen S, Fu S, Preston B, Brandon C,
He S, Shen C, Wu J, Wang S, Xie W, et al: miR-203 suppresses the
proliferation and metastasis of hepatocellular carcinoma by
targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC.
Anticancer Agents Med Chem. 16:414–423. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Minguez B and Lachenmayer A: Diagnostic
and prognostic molecular markers in hepatocellular carcinoma. Dis
Markers. 31:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mann CD, Neal CP, Garcea G, Manson MM,
Dennison AR and Berry DP: Prognostic molecular markers in
hepatocellular carcinoma: A systematic review. Eur J Cancer.
43:979–992. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang N, Yao M, Xu J, Quan Y, Zhang K, Yang
R and Gao WQ: Autocrine activation of CHRM3 promotes prostate
cancer growth and castration resistance via CaM/CaMKK-mediated
phosphorylation of Akt. Clin Cancer Res. 21:4676–4685. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang B, Qi G, Tang F, Yuan S, Wang Z,
Liang X, Li B, Yu S, Liu J, Huang Q, et al: JARID1B promotes
metastasis and epithelial-mesenchymal transition via PTEN/AKT
signaling in hepatocellular carcinoma cells. Oncotarget.
6:12723–12739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs-the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao H, Bai Y, Qiu S, Zheng L, Huang L,
Liu T, Wang X, Liu Y, Xu N, Yan X and Guo H: miR-203 downregulation
is responsible for chemoresistance in human glioblastoma by
promoting epithelial-mesenchymal transition via SNAI2. Oncotarget.
6:8914–8928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu M, Gu M, Zhang K, Zhou J, Wang Z and Da
J: miR-203 inhibition of renal cancer cell proliferation, migration
and invasion by targeting of FGF2. Diagn Pathol. 10:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Y, Ren F, Rong M, Luo Y, Dang Y and
Chen G: Association between underexpression of microrna-203 and
clinicopathological significance in hepatocellular carcinoma
tissues. Cancer Cell Int. 15:622015. View Article : Google Scholar : PubMed/NCBI
|
